Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Montelukast's ability to fight COVID-19 infection.

Literature DB >> 32586154

Montelukast's ability to fight COVID-19 infection.

Andrzej Bozek¹, Janne Winterstein².

Abstract

Montelukast can be effective in the treatment of SARS-CoV-2 infection.

Entities: Chemical Disease

Keywords: Prevention; geriatric

Year: 2020 PMID： 32586154 DOI： 10.1080/02770903.2020.1786112

Source DB: PubMed Journal: J Asthma ISSN： 0277-0903 Impact factor: 2.515

Keyword Cloud
Cited

7 in total

1. Mitochondria Are Potential Targets for the Development of New Drugs Against Neutrophilic Inflammation in Severe Pneumonia Including COVID-19.

Authors: Nina V Vorobjeva; Galina F Sud'ina; Boris V Chernyak
Journal: Front Pharmacol Date: 2021-01-29 Impact factor: 5.810

Review 2. Races of small molecule clinical trials for the treatment of COVID-19: An up-to-date comprehensive review.

Authors: Suwen Hu; Songwei Jiang; Xiang Qi; Renren Bai; Xiang-Yang Ye; Tian Xie
Journal: Drug Dev Res Date: 2021-11-11 Impact factor: 5.004

3. Montelukast Inhibits Platelet Activation Induced by Plasma From COVID-19 Patients.

Authors: Marina Camera; Paola Canzano; Marta Brambilla; G Enrico Rovati
Journal: Front Pharmacol Date: 2022-02-08 Impact factor: 5.810

4. Effects of non-steroidal anti-inflammatory drugs and other eicosanoid pathway modifiers on antiviral and allergic responses: EAACI task force on eicosanoids consensus report in times of COVID-19.

Authors: Milena Sokolowska; G Enrico Rovati; Zuzana Diamant; Eva Untersmayr; Jürgen Schwarze; Zuzanna Lukasik; Florentina Sava; Alba Angelina; Oscar Palomares; Cezmi A Akdis; Liam O'Mahony; Milos Jesenak; Oliver Pfaar; María José Torres; Marek Sanak; Sven-Erik Dahlén; Grzegorz Woszczek
Journal: Allergy Date: 2022-02-25 Impact factor: 14.710

Montelukast's ability to fight COVID-19 infection.

1. Mitochondria Are Potential Targets for the Development of New Drugs Against Neutrophilic Inflammation in Severe Pneumonia Including COVID-19.

Review 2. Races of small molecule clinical trials for the treatment of COVID-19: An up-to-date comprehensive review.

3. Montelukast Inhibits Platelet Activation Induced by Plasma From COVID-19 Patients.

4. Effects of non-steroidal anti-inflammatory drugs and other eicosanoid pathway modifiers on antiviral and allergic responses: EAACI task force on eicosanoids consensus report in times of COVID-19.

5. Montelukast in children with allergic rhinitis amid COVID-19 pandemic.

Review 6. Asthma and COVID-19: What do we know now.

7. The Petasites hybridus CO₂ Extract (Ze 339) Blocks SARS-CoV-2 Replication In Vitro.

Montelukast's ability to fight COVID-19 infection.

1. Mitochondria Are Potential Targets for the Development of New Drugs Against Neutrophilic Inflammation in Severe Pneumonia Including COVID-19.

Review 2. Races of small molecule clinical trials for the treatment of COVID-19: An up-to-date comprehensive review.

3. Montelukast Inhibits Platelet Activation Induced by Plasma From COVID-19 Patients.

4. Effects of non-steroidal anti-inflammatory drugs and other eicosanoid pathway modifiers on antiviral and allergic responses: EAACI task force on eicosanoids consensus report in times of COVID-19.

5. Montelukast in children with allergic rhinitis amid COVID-19 pandemic.

Review 6. Asthma and COVID-19: What do we know now.

7. The Petasites hybridus CO2 Extract (Ze 339) Blocks SARS-CoV-2 Replication In Vitro.

7. The Petasites hybridus CO₂ Extract (Ze 339) Blocks SARS-CoV-2 Replication In Vitro.